Tenet Healthcare stock gained 1.83 percent before Q3 results
Tenet Healthcare stock gained 1.83 percent, closing at USD 258.62 on October 2, 2026, ahead of its Q3 results release scheduled for October 29, 2026. The company reported strong Q2 results with adjusted EPS of USD 6.12 and raised its 2026 adjusted EBITDA guidance. Analysts maintain a "Buy" consensus with an average price target 10.06 percent above the current closing price, despite the company's capital structure involving significant debt refinancing.
Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know
Tenet Healthcare (THC) recently saw its stock price increase by 1.83% to $258.62, outperforming the S&P 500's daily gain. Despite a monthly depreciation, the company is projected to see significant EPS and revenue growth in its upcoming earnings report, with analysts anticipating a 24.05% increase in EPS and 3.4% revenue growth year-over-year. Investors are advised to monitor analyst estimate changes, as these often correlate with future stock performance, and THC currently holds a Zacks Rank of #3 (Hold).
Tenet Healthcare Corporation Actuals & Estimates (HAN:THC1)
This article provides an overview of Tenet Healthcare Corporation (THC1) traded on the Hannover Stock Exchange, including its stock performance, analyst forecasts, financial actuals and estimates, and key financial metrics. It highlights the stock's recent performance, market capitalization, earnings per share, revenue, and EBITDA. The company does not pay dividends and its next earnings report is expected on November 3, 2026.
Here’s How Much You Would Have Made Owning Tenet Healthcare Stock In The Last 10 Years
Tenet Healthcare (NYSE: THC) has significantly outperformed the market over the last decade, with an annualized return of 28.19%. An investment of $100 in THC stock ten years ago would now be worth $1,184.37, demonstrating the power of compounded returns. The company currently holds a market capitalization of $20.74 billion.
THC1 Stock Price and Chart — HAN:THC1
This article provides a comprehensive overview of Tenet Healthcare Corporation (THC1) stock on the Hannover Stock Exchange, including key financial stats, upcoming earnings, company information, and analyst ratings. It details the company's segments, recent strategic moves like hospital sales, and various analyst ideas and forecasts for its stock performance. The article also lists ETFs holding THC1 and answers frequently asked questions about the company's financials and stock trading.
Tenet Healthcare Corporation (THC) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Tenet Healthcare Corporation (THC), including various analyst reports and stock performance data. It highlights different perspectives on THC's valuation, growth sustainability, and comparison with other medical stocks, alongside its year-to-date and multi-year returns against the S&P 500. The stock's performance data shows significant returns for shareholders over the past three years.
Tenet Healthcare (THC) Refinances $2.0b Of Debt, Is The Stock Still Cheap?
Tenet Healthcare (THC) recently refinanced $2.0 billion of debt, issuing new 6.250% senior notes due 2034 to redeem earlier debt. Despite strong long-term share price performance, the stock has seen short-term cooling and trades below analyst targets, raising questions about whether it's undervalued or if the discount reflects lingering risks. The company's focus on cost efficiency and strategic capital deployment, including M&A and share repurchases, aims to sustain free cash flow and improve leverage.
Tenet Healthcare Price Target Announced at $265.00/Share by BMO Capital
BMO Capital has set a price target of $265.00 per share for Tenet Healthcare (NYSE:THC), implying a potential upside of 14.19% from its previous closing price of $232.07. This target is based on the firm's analysis and recommendation, suggesting a positive outlook for the company's stock performance.
BMO Capital Initiates Tenet Healthcare With Market Perform Rating, $265 PT
BMO Capital has initiated coverage on Tenet Healthcare (THC) with a "Market Perform" rating and set a price target of $265. This news comes amidst recent activities for Tenet Healthcare, including a director selling stock for $2.6 million and announcements regarding the upsizing and pricing of senior notes offerings totaling $2 billion and $1.5 billion respectively. The company, a diversified healthcare services provider, continues to see analyst attention following its recent financial activities and outlook presentations.
Tenet Healthcare Issues $2.0 Billion 6.25% Senior Notes Due 2034 to Refinance Debt
Tenet Healthcare has issued $2.0 billion in 6.250% senior notes due 2034 to refinance existing debt. The company plans to use the proceeds to redeem its 5.125% senior secured first lien notes due 2027 and partially redeem its 6.125% senior notes due 2028, aiming to extend maturities and enhance financial flexibility. The transaction is detailed in an SEC filing with the Bank of New York Mellon Trust Company acting as trustee.
New 2034 debt deal reshapes Tenet Healthcare (NYSE: THC) bonds
Tenet Healthcare (THC) has issued $2.0 billion in 6.250% senior notes due 2034 to refinance existing debt. The proceeds, combined with cash on hand, will be used to fully redeem $1.5 billion of 5.125% senior secured first lien notes due November 2027 and partially redeem $0.5 billion of 6.125% senior notes due October 2028. This move reshapes the company's debt maturity profile and introduces new covenants regarding liens, sale-and-leaseback transactions, and significant asset sales.
Tenet Healthcare stock trades at USD 261.99 with 50 hospitals
Tenet Healthcare stock traded at USD 261.99 on September 22, 2026, operating 50 acute care hospitals and an ambulatory platform (USPI) with 538 ambulatory surgery centers and 26 surgical hospitals. USPI's ambulatory business is a significant and profitable part of the company, generating USD 5.2 billion in revenue and USD 2 billion in adjusted EBITDA in fiscal year 2025. The company plans to continue investing significantly in ambulatory surgery center acquisitions.
Tenet Healthcare Corporation Issues $2,000,000,000 Of 6.250% Senior Notes Due 2034
Tenet Healthcare Corporation has issued $2 billion of 6.250% senior notes due in 2034. The net proceeds from this offering, combined with cash on hand, will be used to redeem $1.5 billion of its 5.125% senior secured first lien notes due 2027 and partially redeem $0.5 billion of its 6.125% senior notes due 2028. The indenture includes covenants restricting the company's ability to incur liens, engage in sale and lease-back transactions, or consolidate, merge, or sell assets, with certain exceptions.
Likely contenders emerge for hospital site
Developers planning a new hospital at State Road 60 and 66th Avenue in Vero Beach indicate that three major hospital systems are interested in occupying the site. While the names are undisclosed, AdventHealth, HCA Florida, and Tenet Healthcare are identified as likely contenders based on their presence in Florida, financial stability, and interest in the Vero Beach market. The article details the financial health and operational scope of each potential candidate, highlighting their suitability for the proposed facility.
Tenet Healthcare director J. Robert Kerrey sells $3.17m in stock
Tenet Healthcare director J. Robert Kerrey sold common stock valued at approximately $3.17 million on September 14, 2026. This transaction involved 12,010 shares, with prices ranging from $262.43 to $265.02 per share. Following the sale, Kerrey beneficially owns 4,794 shares, while the company's stock trades near its 52-week high with a 33.75% year-to-date return and various analysts have raised their price targets for THC.
Tenet Healthcare Shares Fall 2.3% After Director Sells $2.63 Million of Stock
Tenet Healthcare Corporation (NYSE:THC) shares dropped 2.3% in premarket trading after director Richard Mark sold 10,000 shares for approximately $2.63 million. The sale was executed at a weighted average price of $263.42 per share, and Mark still beneficially owns 25,121 shares. The regulatory filing did not provide a reason for the transaction.
Tenet Healthcare director Richard Mark sells $2.63m in company stock
Richard J. Mark, a director at Tenet Healthcare Corp. (NASDAQ:THC), sold 10,000 shares of the company’s common stock for $2.63 million on September 10, 2026. This transaction occurred as the stock trades near its 52-week high, yet InvestingPro analysis suggests it remains undervalued. The sale follows Tenet Healthcare's strong second-quarter 2026 results and raised full-year outlook, which led several investment firms to increase their price targets for the company.
Conifer to lay off over 1,000 workers
Conifer Health Solutions, a revenue cycle subsidiary of Tenet Healthcare, is set to lay off over 1,000 primarily remote employees by November 2. These layoffs are largely a consequence of CommonSpirit's decision to terminate its service contract with Conifer and exit its stake in the company. Tenet had regained full ownership of Conifer in February after CommonSpirit moved to insource its revenue cycle functions, a deal that leadership initially presented as mutually beneficial and an opportunity to invest in AI and automation.
Tenet Healthcare offers $1.5B notes to refinance 2027 debt
Tenet Healthcare Corporation announced a private placement offering of $1.5 billion in senior notes due 2034. The company plans to use the proceeds, along with cash on hand, to redeem its outstanding 5.125% senior secured first lien notes due November 2027. This refinancing aims to manage its existing debt obligations.
Tenet Healthcare prices $2 billion senior notes offering By Investing.com
Tenet Healthcare Corporation announced the pricing of a $2 billion senior notes offering due September 15, 2034, with an interest rate of 6.250% per annum. The company plans to use the net proceeds, along with cash on hand, to redeem existing senior secured first lien notes and partially redeem other senior notes. The offering, which was increased from $1.5 billion, is expected to close on September 22, 2026.
Tenet Healthcare Corporation Announces Upsizing and Pricing of Its $2.0 Billion Private Offering of Senior Notes
Tenet Healthcare Corporation announced the pricing and upsizing of its private offering of senior notes from $1.5 billion to $2.0 billion. These notes, due September 15, 2034, will bear interest at 6.250% per annum. The company plans to use the net proceeds, along with cash on hand, to redeem its outstanding 5.125% senior secured first lien notes due November 2027 and partially redeem its 6.125% senior notes due October 2028.
Tenet Healthcare offers $1.5B notes to refinance 2027 debt By Investing.com
Tenet Healthcare Corporation announced a private placement offering of $1.5 billion in senior notes due 2034. The company intends to use the proceeds, combined with cash on hand, to redeem all outstanding 5.125% senior secured first lien notes due November 2027. The new notes will be unsecured obligations, ranking equally with existing and future senior unsecured obligations.
Tenet Healthcare (NYSE:THC) Looks Like a Decent Value Stock With Strong Profitability
Tenet Healthcare (NYSE:THC) is highlighted as a decent value stock due to its low earnings multiple and strong profitability metrics compared to industry peers. The company exhibits attractive valuation scores and excellent profitability, although its financial health and growth are rated moderately due to its debt levels. Despite the debt, the company's strong free cash flow and operational efficiency make it an interesting candidate for value investors.
Tenet Healthcare director Nadja West sells $298,137 in stock
Tenet Healthcare director Nadja West sold 1,152 shares of common stock for $298,137 on September 2, 2026. Following the sale, she directly holds 23,653 shares. The transaction occurred while THC stock was trading near its 52-week high, and comes after the company reported strong Q2 2026 results and received raised price targets from several analysts.
Tenet Healthcare and Archrock have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has named Tenet Healthcare (THC) as its Bull of the Day due to its strong financial performance, rising EPS estimates, and attractive valuation within the defensive healthcare sector. Conversely, Archrock (AROC), a natural gas compression specialist, was designated the Bear of the Day following consecutive earnings misses, reduced guidance, and broad-based downward EPS revisions despite its exposure to the energy sector. The article also touches on other companies like NextEra Energy (NEE), FirstEnergy (FE), and PPL Corp (PPL), highlighting how AI-driven data center growth is impacting their backlogs and strengthening long-term prospects for utilities.
Tenet Healthcare COO Lisa Foo sells $6.39m in shares By Investing.com
Lisa Foo, COO of Tenet Healthcare Corp, sold 24,000 shares of the company's stock for approximately $6.39 million on August 31, 2026. This sale occurred while the stock was trading near its 52-week high, despite an InvestingPro analysis suggesting it remains undervalued. The company recently reported strong Q2 2026 results and received raised price targets from several analyst firms.
Tenet to Participate in the Wells Fargo Healthcare Conference
Tenet Healthcare Corporation (NYSE: THC) is scheduled to present at the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 12:45 p.m. Eastern Time. A live webcast and audio archive of the event will be accessible through the investor relations section of Tenet's website for 30 days. Tenet Healthcare is a diversified healthcare services company operating a network of ambulatory surgery centers, hospitals, and other facilities, including its Conifer Health Solutions subsidiary.
This Insider Has Just Sold Shares In Tenet Healthcare
The article "This Insider Has Just Sold Shares In Tenet Healthcare" is missing its main content. It appears to be a placeholder or a partially scraped page from Sahm Capital Financial Company, a licensed entity in Riyadh, KSA. The available content only includes navigation links, company information, and legal disclaimers.
Tenet healthcare director Cecil Haney sells $361,438 in stock
Tenet Healthcare director Cecil D. Haney sold 1,300 shares of company stock for $361,438 on August 24, 2026, near its 52-week high. This sale follows a strong 50.7% return for THC shares over the past year and recent positive Q2 2026 results that led several analyst firms to raise their price targets. Mr. Haney still directly owns 12,553 shares after the transaction.
Tenet Healthcare (NYSE: THC) holder plans new sale after $13.9M trade
Saumya S. Sutaria, an insider at Tenet Healthcare Corp (THC), intends to sell 50,000 common shares of the company through Fidelity Brokerage Services LLC on August 25, 2026. These shares are linked to restricted stock vesting awards. The filing also reports a prior sale of 50,000 shares on August 24, 2026, with an aggregate value of $13,935,240.26.
Tenet Healthcare (NYSE: THC) director lines up $361K share sale
Tenet Healthcare (NYSE: THC) director Cecil D. Haney has filed a Form 144 notice to sell 1,300 shares of common stock, valued at $361,439.00, through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of August 24, 2026. The shares were acquired as compensation from restricted stock vesting events in 2024 and 2025. This transaction indicates an insider selling a portion of their holdings.
Tenet Healthcare (THC): Sutaria files 50,000-share resale notice
Saumya S. Sutaria has filed a Rule 144 notice to resell 50,000 shares of Tenet Healthcare (THC) common stock through Fidelity Brokerage Services LLC. The shares, acquired as compensation through restricted stock vesting in early 2025, have an aggregate market value of over $13.9 million, with an approximate sale date of August 24, 2026. This filing represents a neutral impact and sentiment, as it pertains to the liquidation of vested compensation.
Tenet Healthcare (THC) Stock Jumped, What Is Behind The Fresh Attention?
Tenet Healthcare (THC) stock has seen significant momentum with a 20.4% return over 30 days and a 56.4% one-year total shareholder return, drawing renewed investor attention to its hospital and outpatient network and capital allocation. Despite this, a common narrative suggests the stock is 12.3% overvalued with a fair value of $250.00 compared to its current price of $280.77. However, the article also notes that THC trades at a P/E of 10.1x, significantly lower than its fair ratio of 18x and industry averages, suggesting potential undervaluation or investor skepticism about its current earnings.
Tenet Healthcare Corporation (THC) Stock Analysis: Strong Buy Ratings Propel Investor Confidence
Tenet Healthcare Corporation (THC) is attracting significant investor attention due to strong buy ratings and robust financial performance. The company, operating in the medical care facilities industry, boasts a market capitalization of $22.61 billion and is trading near its 52-week high, supported by 6.80% revenue growth and a strong forward P/E ratio of 13.47. Analysts are overwhelmingly positive, with 19 buy ratings and an average target price suggesting further appreciation potential.
Tenet Healthcare (THC) Stock May Be 49% Undervalued After Raised Outlook
Tenet Healthcare (THC) stock appears significantly undervalued, with a Discounted Cash Flow (DCF) model suggesting a 49.3% intrinsic discount after the company raised its outlook for free cash flow and profitability. The stock also trades at a P/E ratio of 10.1x, well below the healthcare sector average of 25.5x and its estimated fair P/E of 18.0x, indicating further undervaluation. While the company has seen strong returns over the past three years, these valuation metrics suggest there may still be upside potential, depending on sustained profitability and execution.
Tenet Healthcare Corp (THC) Stock Up 3.0% but GF Value Says Over
Tenet Healthcare Corp (THC) shares rose 3.0% to $280.77, nearing its 52-week high, but GuruFocus's GF Value™ indicates the stock is 51.6% overvalued at $185.19. Despite a strong GF Score™ of 74/100, concerns arise from its high P/E ratio compared to historical averages and significant insider selling, suggesting caution for investors. While some gurus are increasing positions, the overvaluation and insider activity warrant careful consideration before investing.
Tenet Healthcare (THC) Stock Still Looks Like A Bargain On A 272% Run
Despite a 272% stock increase over the past three years, Tenet Healthcare (THC) appears undervalued, with its P/E ratio significantly lower than the healthcare sector average and a model-based fair P/E. The company's recent strong Q2 2026 earnings and raised full-year outlook suggest that its current share price has not fully priced in these positive developments. The ongoing debate centers on whether Tenet Healthcare can sustain its current margin and volume profile to maintain its earnings power and potentially drive further upside in its valuation.
Tenet Healthcare (NYSE:THC) Stock Price
Tenet Healthcare (NYSE:THC) is currently trading at US$268.52, with a fair value estimate of US$250, indicating it is overvalued by 7.4%. Analyst narratives provide varying perspectives, with some highlighting growth drivers like behavioral care and outpatient trends, while others caution about M&A risks and Medicaid reliance. Recent insider transactions show net selling activity.
Tenet Healthcare stock hits all-time high at 270.79 USD By Investing.com
Tenet Healthcare's stock reached an all-time high of $270.79 USD, reflecting a 54.4% increase over the past year and strong investor confidence. The company's P/E ratio of 10.46 and PEG ratio of 0.15 suggest an attractive valuation. Recent strong Q2 2026 results and raised full-year outlook have led several analysts to increase their price targets, indicating a positive outlook for the company's financial trajectory.
Can Tenet Healthcare's Hospital Growth Keep Earnings Momentum Going?
Tenet Healthcare's (THC) Hospital Operations segment continues to drive strong earnings, with adjusted admissions increasing 2.6% year over year and revenue per adjusted admission rising 3.3% in Q2 2026. This growth is attributed to healthy patient demand, a better mix of services, and a focus on higher-acuity care, leading to a significant 22.3% jump in hospital adjusted EBITDA. Despite some pressure from weaker exchange enrollment, the company's cost-management efforts and a positive outlook for continued improvement position the segment as a strong tailwind for THC's earnings.
Can Tenet Healthcare's Hospital Growth Keep Earnings Momentum Going?
Tenet Healthcare Corporation's Hospital Operations segment showed strong earnings growth in Q2 2026, with increased adjusted admissions and revenue per patient, leading to significant margin improvement. Despite some pressure from weaker exchange enrollment, the company's focus on high-acuity care, cost management, and strong commercial revenues are driving profitability. Peers like Universal Health Services and HCA Healthcare also reported solid hospital growth, indicating a healthy demand for hospital care.
Tenet Healthcare director Roy Blunt sells $157,608 in company stock
Tenet Healthcare director Roy Blunt sold 600 shares of company stock for $157,608 on August 5, 2026, at an average price of $262.68 per share. This transaction occurred while the stock was trading near its 52-week high, despite analysis suggesting it remains undervalued. The sale follows Tenet Healthcare's strong second-quarter 2026 results and raised full-year outlook, which led to multiple analyst price target increases.
Tenet Healthcare director Roy Blunt sells $157,608 in company stock
Tenet Healthcare director Roy Blunt sold 600 shares of company stock worth $157,608 on August 5, 2026, with the stock trading near its 52-week high. This sale follows Tenet Healthcare's strong second-quarter 2026 results, which surpassed Wall Street expectations and led to raised full-year outlooks and increased price targets from several analyst firms.
Tenet Healthcare (NYSE:THC) Lowered to "Buy" Rating by Wall Street Zen
Wall Street Zen downgraded Tenet Healthcare (NYSE:THC) from a "strong-buy" to a "buy" rating, despite the broader analyst consensus remaining a "Moderate Buy" with an average price target of $273. The company recently reported strong quarterly earnings of $6.12 per share, exceeding estimates, with revenue increasing 6.8% year over year to $6.04 billion. Insiders have sold nearly $9.8 million in stock in the past 90 days, while institutional investors hold 95.44% of the shares.
Are Investors Undervaluing Tenet Healthcare (THC) Right Now?
Tenet Healthcare (THC) is currently considered a strong value stock, boasting a Zacks Rank #1 (Strong Buy) and an "A" grade for Value. Key metrics like a PEG ratio of 0.81 (compared to an industry average of 1.56), a P/B ratio of 3.07 (vs. industry 3.67), and a P/CF ratio of 7.51 (vs. industry 8.96) suggest that the stock may be undervalued. These indicators, combined with a strong earnings outlook, position THC as an attractive investment for value-oriented investors.
Is Tenet Healthcare (THC) Overvalued Following Higher 2026 Adjusted EPS Guidance?
Tenet Healthcare (THC) has seen a significant surge in its share price and an increase in its 2026 adjusted EPS guidance, leading to questions about its valuation. While some analysts deem it overvalued at $250 compared to its last close of $267.05, others note its P/E ratio is lower than the industry average, suggesting potential mispricing or reflecting its high debt. The stock presents a mixed sentiment with strong momentum balanced against identified risks and rewards.
Tenet Healthcare (THC) Could Be 7% Above Fair Value As Golden Cross Draws Focus
Tenet Healthcare (THC) recently experienced a "golden cross," with its 50-day moving average surpassing its 200-day average, signaling positive momentum. Despite a significant stock price increase, analysts project the company to be 6.7% overvalued, with a fair value of $250 against its current trading price of $266.79. However, the article notes that THC's P/E ratio is considerably lower than its peers, suggesting potential for either risk or opportunity.
Tenet Healthcare (NYSE:THC) Rating Increased to Strong-Buy at Zacks Research
Zacks Research has upgraded Tenet Healthcare (NYSE:THC) from a "hold" to a "strong-buy" rating. This upgrade comes after Tenet reported strong quarterly earnings, beating analyst estimates with $6.12 earnings per share and revenue of $6.04 billion. Despite recent insider stock sales totaling $9.8 million, institutional investors hold a significant 95.44% stake in the company.
Assenagon Asset Management S.A. Lowers Stock Position in Tenet Healthcare Corporation $THC
Assenagon Asset Management S.A. significantly reduced its stake in Tenet Healthcare Corporation ($THC) by 60.7% in the second quarter, selling 74,968 shares but still retaining 48,533 shares valued at approximately $9.08 million. Despite this, institutional investors collectively own 95.44% of THC, and Wall Street analysts maintain a "Moderate Buy" consensus rating with an average price target of $272.25. The company recently reported strong quarterly earnings, beating analyst estimates, although insiders have sold a substantial amount of shares.
Here's How Much You'd Have If You Invested $1000 in Tenet Healthcare a Decade Ago
An investment of $1000 in Tenet Healthcare (THC) ten years ago would now be worth $10,130.81, representing a 913.08% gain, outperforming the S&P 500 and gold. The company benefits from higher-acuity services, strong commercial revenues, and the expansion of its ambulatory care platform, USPI. Despite concerns about labor costs and valuation, analysts forecast further upside for THC.
